



## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Co	r Fax Existing Chart	PRESCRIBER INFORMATION				
Name: DOB: Address: City, State, Zip: Alt. Phone: Email: SS#:			State License: Tax ID:			
Gender:   M   F Weight:(lbs) Ht:			Phone:	Phone:            Office Contact:            Phone:		
Allergies:						
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)						
Primary Insurance:Plan #:						
Group #:						
RX Card (PBM):						
BIN:		BIN:	PCN:			
CLINICAL INFORMATION						
Primary ICD-10 Code: Secondary ICD-10 Code			ode:	Tertiary ICD-10 Code:		
Transplant Date: Epstein-Barr Virus (EBV): 🗆 Seropositive 🗀 Seronegative or unknown (contra-indicated)						
Will Nulojix be used with basiliximab induction, mycophenolate mofetil, and corticosteroids? $\square$ Yes $\square$ No						
Is patient not able to tolerate cyclosporine or tacrolimus due to allergy or intolerance? $\ \square$ Yes $\ \square$ No						
NULOJIX® ORDERS						
Prescription type: $\square$ New start $\square$ Restart $\square$		☐ Continued therapy	ontinued therapy Total Doses Received: Date of		ast Injection/Infusion:	
Medication			Dose/Frequency		Refills	
<ul> <li>□ Nulojix® (belatacept) initial dosing</li> <li>□ Nulojix® (belatacept) maintenance dosing</li> </ul>		<ul> <li>□ 10 mg/kg to nearest 12.5 mg increment IV over 30 minutes on day 1 before transplantation, on day 5 approximately 96 hours after the first dose, and at the end of weeks 2, 4, 8, and 12.</li> <li>□ 5 mg/kg to nearest 12.5 mg-increment IV over 30 minutes at the end of week 16 and every 4 weeks +/- 3 days thereafter</li> <li>□ Other:</li> </ul>		Refills:		
Pre-Medication	Dose/Strength		Directions		ns.	
☐ Acetaminophen	□ 500mg		☐ Take 1-2 tablets PO prior to infusion or post-infusion as directed			
	☐ 25mg IV/PO		☐ Take 1 tablet PO prior to infusion or as directed OR			
	□ 50mg IV/PO		☐ Inject contents of 1 vial IV prior to infusion or as directed			
☐ Methylprednisolone	□ 40mg □ 100mg		☐ Inject contents of 1 vial IV prior to infusion or as directed			
	☐ 125mg		☐ Other: Inject 100mg IV 30 minutes prior to infusion			
<b></b>						
INFUSION REACTION ORDERS						
Mild reaction protocol:  ☑ Diphenhydramine 25mg IV, one time, for pruritus.						

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



## **NULOJIX®**

## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

Date: \_\_\_\_\_

Please Send a Copy of The Patient's Up-to-Date Clinical Notes If symptoms worsen, see orders for moderate to severe reactions. Moderate reaction protocol: ☐ Acetaminophen 650mg PO, one time, for pyrexia or rigors ☑ Diphenhydramine 50mg IV, one time, for pruritus or urticaria ☑ Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms If symptoms worsen, see interventions for severe reactions Severe reaction protocol: (Call 911 if initiated): ☐ Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%) ☑ Diphenhydramine 50mg IV,one time, for respiratory symptoms, edema, or anaphylaxis Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis ☑ Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen **FLUSHING & LOCKING ORDERS** Flushing Protocol (>66lbs/33kg) PIV and Midline: Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter: ☑ 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL ☑ 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion IV flush after infusion/lab draw Locking Protocol (>66lbs/33kg) PIV and Midline: PICC: Implanted Port, Tunneled Catheter, and Nontunneled Catheter: ☑ Heparin Sodium 10 units/mL 1mL IV final ☐ Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush flush post normal saline flush □ Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush \*\* May substitute Dextrose 5% in Water, or alternative, for 0.9& Sodium Chloride, when indicated due to incompatibility with medications bring infused **SIGNATURE** We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

**Prescriber Signature** 

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.